[8-K] Axiom Intelligence Acquisition Corp 1 Units Reports Material Event

Rhea-AI Filing Summary

GSK plc (Form 6-K) reports another execution under its 4 June 2025 non-discretionary share-buy-back mandate. On 30 July 2025 the company, via Merrill Lynch International, repurchased 288,978 ordinary shares (nominal 31¼ p) on the London Stock Exchange at prices ranging 1,386.50 p – 1,463.50 p, delivering a volume-weighted average price of 1,432.69 p.

Since the programme’s launch, GSK has acquired 18,435,938 shares. Following the latest trade the company now holds 236,570,321 shares in treasury and has 4,078,815,089 shares in issue (excluding treasury). The treasury balance equals 5.80 % of total voting rights, leaving the same number (4,078,815,089) of votes outstanding. All repurchased shares are retained as treasury stock.

Positive

• Continuation of share-buy-back programme: 288,978 shares bought at 1,432.69 p VWAP, lifting total 2025 purchases to 18.4 m and treasury stock to 5.8 % of voting rights.

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine daily buy-back; limited standalone impact on valuation.

The 289 k-share purchase cost roughly £4.1 m and represents just 0.007 % of GSK’s outstanding equity, keeping liquidity effects negligible. Cumulative purchases since 4 June (~18.4 m shares, c. £260 m) bring treasury holdings to 5.8 % of voting rights, still within UK thresholds. While the programme supports mild EPS accretion and signals ongoing capital returns, today’s disclosure does not materially change leverage, cash reserves, or strategic flexibility. I therefore classify the filing as informational and neutral for investors.

false 0002057030 0002057030 2025-07-31 2025-07-31 0002057030 AXINU:UnitsEachConsistingOfOneClassOrdinaryShareAndOneRightMember 2025-07-31 2025-07-31 0002057030 AXINU:ClassOrdinarySharesParValue0.0001PerShareMember 2025-07-31 2025-07-31 0002057030 AXINU:RightsEachRightEntitlingHolderToReceiveOnetenth110OfOneClassOrdinaryShareMember 2025-07-31 2025-07-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): July 31, 2025

AXIOM INTELLIGENCE ACQUISITION CORP 1

(Exact name of registrant as specified in its charter)

Cayman Islands		001-42708		98-1849669
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

Berkeley Square House, 2nd Floor
Berkeley Square

London W1J 6BD

United Kingdom

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: +44 20 3973 7928

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Units, each consisting of one Class A ordinary share and one right		AXINU		The Nasdaq Stock Market LLC
Class A ordinary shares, par value $0.0001 per share		AXIN		The Nasdaq Stock Market LLC
Rights, each right entitling the holder to receive one-tenth (1/10) of one Class A ordinary share		AXINR		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

Separate Trading of Class A Ordinary Shares and Rights

On July 31, 2025, Axiom Intelligence Acquisition Corp 1 (the “Company”) announced that, commencing on August 1, 2025, the holders of the units issued in its initial public offering (the “Units”), each Unit consisting of one Class A ordinary share of the Company, par value $0.0001 per share (the “Class A Ordinary Share”), and one right to receive one-tenth (1/10) of one Class A Ordinary Share upon the consummation of the Company’s initial business combination (each, a “Share Right”), may elect to separately trade the Class A Ordinary Shares and the Share Rights included in the Units. The Class A Ordinary Shares and the Share Rights are expected to trade on the Nasdaq Global Market under the symbols “AXIN” and “AXINR”, respectively. Any Units not separated will continue to trade on the Nasdaq Global Market under the symbol “AXINU.” Holders of Units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company’s transfer agent, in order to separate the Units into Class A Ordinary Shares and Share Rights.

Item 9.01. Financial Statements and Exhibits.

(d)  Exhibits

Exhibit No.		Description
99.1		Press Release, dated July 31, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	AXIOM INTELLIGENCE ACQUISITION CORP 1
	By:	/s/ Douglas Ward
		Name:	Douglas Ward
		Title:	Chief Executive Officer
Dated: July 31, 2025

2

FAQ

How many GSK (GSK) shares were repurchased on 30 July 2025?

The company bought 288,978 ordinary shares.

What price did GSK pay for the shares?

Prices ranged from 1,386.50 p to 1,463.50 p with a VWAP of 1,432.69 p.

How many shares has GSK bought since 4 June 2025?

A cumulative 18,435,938 shares have been repurchased under the current programme.

What is GSK’s current treasury share balance?

After the transaction, GSK holds 236,570,321 shares in treasury.

What percentage of voting rights do treasury shares represent?

Treasury shares account for 5.80 % of total voting rights.

How many GSK shares remain in circulation?

There are 4,078,815,089 ordinary shares in issue, all carrying voting rights.